hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy.
about
hERG1 positivity and Glut-1 negativity identifies high-risk TNM stage I and II colorectal cancer patients, regardless of adjuvant chemotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
hERG1 positivity and Glut-1 ne ...... less of adjuvant chemotherapy.
@en
hERG1 positivity and Glut-1 ne ...... less of adjuvant chemotherapy.
@nl
type
label
hERG1 positivity and Glut-1 ne ...... less of adjuvant chemotherapy.
@en
hERG1 positivity and Glut-1 ne ...... less of adjuvant chemotherapy.
@nl
prefLabel
hERG1 positivity and Glut-1 ne ...... less of adjuvant chemotherapy.
@en
hERG1 positivity and Glut-1 ne ...... less of adjuvant chemotherapy.
@nl
P2093
P2860
P356
P1476
hERG1 positivity and Glut-1 ne ...... less of adjuvant chemotherapy.
@en
P2093
Annarosa Arcangeli
Elena Lastraioli
Francesco Di Costanzo
Gianluca Bartoli
Giulia Petroni
Jessica Iorio
Leonardo Muratori
Lorenzo Antonuzzo
Luca Messerini
P2860
P304
P356
10.2147/OTT.S114090
P407
P577
2016-10-14T00:00:00Z